• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genetron Holdings Limited

    3/28/24 1:26:40 PM ET
    $GTH
    Medical Specialities
    Health Care
    Get the next $GTH alert in real time by email
    6-K 1 tm2331317d7_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of March 2024

     

    Commission File Number: 001-39328

     

     

     

    Genetron Holdings Limited

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    1-2/F, Building 11, Zone 1

    No.8 Life Science Parkway

    Changping District, Beijing, 102206

    People’s Republic of China

    +86 10 5090-7500

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x                  Form 40-F ¨

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Genetron Holdings Limited
         
      By: /s/ Sizhen Wang
      Name: Sizhen Wang
      Title: Chief Executive Officer

     

    Date: March 28, 2024

     

     

      

    EXHIBIT INDEX

     

    Exhibit   Description
    99.1   Press Release titled “Genetron Health Announces Completion of Going Private Transaction”

     

     

    Get the next $GTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genetron Health Announces Completion of Going Private Transaction

    BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the "Merger") with Genetron New Co Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and wil

    3/28/24 1:30:11 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Shareholders' Approval of Merger Agreement

    BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Genetron New Co Limite

    2/21/24 6:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Hold Extraordinary General Meeting of Shareholders

    BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and

    1/17/24 6:05:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    SEC Filings

    View All

    SEC Form 15-12G filed by Genetron Holdings Limited

    15-12G - Genetron Holdings Ltd (0001782594) (Filer)

    4/8/24 6:04:10 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Genetron Holdings Limited

    S-8 POS - Genetron Holdings Ltd (0001782594) (Filer)

    3/29/24 6:02:34 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form 25-NSE filed by Genetron Holdings Limited

    25-NSE - Genetron Holdings Ltd (0001782594) (Subject)

    3/28/24 4:24:30 PM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Leadership Updates

    Live Leadership Updates

    View All

    Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the "Special Committee") of the Company's Board of Directors (the "Board") has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice) as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel. The Special Committee was formed to evaluate and consider the previously announced preliminary

    9/2/22 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

    --Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- --Announces exclusive license of TellDx platform to Genetron Holdings Limited for China-- --Secures Deployment of TellDx at ARUP Laboratories, Inc-- BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A

    5/10/21 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Financials

    Live finance-specific insights

    View All

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re

    6/2/22 7:19:58 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

    BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528

    5/23/22 4:05:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

    BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.

    3/29/22 7:26:05 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/2/24 5:44:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/1/24 4:15:35 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    3/29/24 8:04:05 AM ET
    $GTH
    Medical Specialities
    Health Care